Kraisangka J., Druzdzel M.J., Lohmueller L.C., Kanwar M.K., Antaki J.F., Benza R.L. (2019) Bayesian Network vs. Cox’s Proportional Hazard Model of PAH Risk: A Comparison. In: Riaño D., Wilk S., ten Teije A. (eds) Artificial Intelligence in Medicine. AIME 2019. Lecture Notes in Computer Science, vol 11526. Springer, Cham Abstract Pulmonary arterial hypertension (PAH) is […]
The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.
Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. Current Hypertension Reports. 2019 Apr 25;21(6):45. doi: 10.1007/s11906-019-0950-y. Review. PMID: 31025123 Abstract PURPOSE OF REVIEW: Pulmonary arterial hypertension (PAH) is a chronic, progressive, and incurable disease with significant morbidity and mortality. Despite increasingly available treatment options, PAH patients continue to experience disease progression and increased […]
ISHLT: Derivation of a Bayesian Network Model from an Existing Risk Score Calculator for Pulmonary Arterial Hypertension
Purpose: We propose an alternative approach to the extensively validated REVEAL risk score calculator using Bayesian network (BN) modeling. We derived a BN model with the same variables and discretization cut points as the REVEAL risk score calculator and data from the REVEAL registry. This study compared the performance and relative impact of the variables […]
The PHORA project is conducting a study on clinician needs and usage of decision support tools for risk assessment and management of patients with PAH. Clinicians are invited to try out the latest version of PHORA and give feedback to the PHORA team at the PHA’s 2018 International PH Conference & Scientific Sessions in the […]
ISHLT Presentation: Application of Bayesian Model to Predict Outcomes in Pulmonary Arterial Hypertension
Dr. Manreet Kanwar presents at the International Society for Heart and Lung Transplantation 38th Annual Meeting and Scientific Sessions. View Full Abstract
Upcoming ISHLT Presentation: DEBATE (Con): The ERS/ESC Risk Profiles are Superior to the REVEAL Calculator for Providing Goal Directed Therapy in PAH
Dr. Raymond Benza presents at the International Society for Heart and Lung Transplantation 38th Annual Meeting and Scientific Sessions.
Authors: Raymond L. Benza MD, Lisa Carey Lohmueller, Jidapa Kraisangka, Manreet Kanwar MD Pulmonary arterial hypertension (PAH) is a chronic and rapidly progressive disease that is characterized by extensive narrowing of the pulmonary vasculature, leading to increases in pulmonary vascular resistance, subsequent right ventricular dysfunction, and eventual death. There are currently multiple approved drugs—developed as single or combination […]
We are pleased to announce that Bayer is collaborating with us on PHORA. Bayer data experts will incorporate recent clinical trials such as PATENT 1 and PATENT 2 in the PHORA predictive models.
We are pleased to announce that Acetlion is collaborating with us on PHORA. Actelion data experts will incorporate recent clinical trials such as REVEAL & REVEAL 2.0, EARLY, BREATH, SERAPHIN and GRIPHON in the PHORA predictive models.
We are pleased to announce that United Therapeutics is collaborating with us on PHORA. United Therapeutics data experts will incorporate recent clinical trials such as TRIUMPH and SC Treprostinil data in the PHORA predictive models.